Journal Article
. 2011 Dec; 21(3):276-83.
doi: 10.1016/j.breast.2011.11.003.

Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy

J L Wright 1 I M Reis  W Zhao  J E Panoff  C Takita  V Sujoy  C R Gomez  M Jorda  D Franceschi  J Hurley  
  • PMID: 22178596
  •     11 citations


Introduction: We assessed racial differences in progression-free survival (PFS) and overall survival (OS) in relation to subtype in uniformly treated stage II-III breast cancer patients.

Methods: We reviewed records of 582 patients receiving post-mastectomy radiation (PMRT) between 1/1999 and 12/2009 and evaluated the effect of demographic, tumor, and treatment characteristics on PFS and OS.

Results: Median follow up was 44.7 months. 24% of patients were black and 76% white. All had mastectomy and PMRT; 98% had chemotherapy; Estrogen receptor (ER)+ patients received endocrine therapy. Black patients were more likely to have ER- (56% vs. 38%, p=0.0001), progesterone receptor (PR)- (69% vs. 54%, p = 0.002), and triple negative (TN) (46% vs. 24%, p < 0.0001) tumors. Overall, black patients had worse PFS (60.6% vs. 78.3%, p = 0.001) and OS (72.8% vs. 87.7%, p < 0.0001). There was no racial difference in PFS (p = 0.229 and 0.273 respectively) or OS (p = 0.113 and 0.097 respectively) among ER- or TN. Among ER+, black patients had worse PFS (55% vs. 81%, p < 0.001) and OS (73% vs. 91%, p < 0.0001). The difference in PFS was seen in the ER+/PR+/HER2- subgroup (p = 0.002) but not ER+/PR-/HER2- (p = 0.129), and in the post-menopausal ER+/HER2- subgroup (p = 0.004) but not pre/peri-menopausal ER+/HER2- (p = 0.150).

Conclusions: Black women had worse survival outcomes in this cohort. This disparity was driven by (1) a higher proportion of ER- and TN tumors in black women and (2) worse outcome of similarly treated black women with ER+ breast cancer. The underlying causes of racial disparity within hormone receptor categories must be further examined.

Breast cancer clinical characteristics and outcomes in Trinidad and Tobago.
Marlene Camacho-Rivera, Camille Ragin, +2 authors, Emanuela Taioli.
J Immigr Minor Health, 2013 Oct 23; 17(3). PMID: 24146313
TREC to WHERE? Transdisciplinary Research on Energetics and Cancer.
Kathryn H Schmitz, Sarah Gehlert, +8 authors, Linda C Nebeling.
Clin Cancer Res, 2016 Jan 23; 22(7). PMID: 26792261    Free PMC article.
"An addendum to breast cancer": the triple negative experience.
Yasemin E Turkman, Holly Powell Kennedy, Lyndsay N Harris, M Tish Knobf.
Support Care Cancer, 2016 Apr 03; 24(9). PMID: 27037812
The Effect of Patient and Contextual Characteristics on Racial/Ethnic Disparity in Breast Cancer Mortality.
Richard Sposto, Theresa H M Keegan, +13 authors, Anna H Wu.
Cancer Epidemiol Biomarkers Prev, 2016 May 20; 25(7). PMID: 27197297    Free PMC article.
Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians.
Foluso O Ademuyiwa, Yu Tao, +2 authors, Cynthia X Ma.
Breast Cancer Res Treat, 2016 Dec 05; 161(3). PMID: 27915434    Free PMC article.
Racial disparity in metabolic regulation of cancer.
Kuldeep S Attri, Divya Murthy, Pankaj K Singh.
Front Biosci (Landmark Ed), 2017 Feb 16; 22. PMID: 28199202    Free PMC article.
Biospecimen donation among black and white breast cancer survivors: opportunities to promote precision medicine.
Vanessa B Sheppard, Alejandra Hurtado-de-Mendoza, +10 authors, Mahlet Tadesse.
J Cancer Surviv, 2017 Nov 18; 12(1). PMID: 29147853
Does race predict survival for women with invasive breast cancer?
Siún M Walsh, Emily C Zabor, +2 authors, Mary L Gemignani.
Cancer, 2019 Jun 18; 125(18). PMID: 31206623    Free PMC article.
Breast cancer in young black women.
S M Walsh, E C Zabor, +3 authors, M L Gemignani.
Br J Surg, 2020 Jan 26; 107(6). PMID: 31981221    Free PMC article.
Literature review of data-based models for identification of factors associated with racial disparities in breast cancer mortality.
Diana Prieto, Milton Soto-Ferrari, +10 authors, Earl Norman.
Health Syst (Basingstoke), 2018 Mar 11; 8(2). PMID: 31275571    Free PMC article.
Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis.
Elizabeth M Salvo, Abril Oliva Ramirez, +4 authors, Imtiaz A Samjoo.
Breast, 2021 Mar 08; 57. PMID: 33677313    Free PMC article.
Systematic Review.